“The Complicated Urinary Tract Infection market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Complicated Urinary Tract Infection pipeline products will significantly revolutionize the Complicated Urinary Tract Infection market dynamics”
The Complicated Urinary Tract Infection market report provides current treatment practices, emerging complicated urinary tract infection drugs, market share of the individual therapies, current and forecasted complicated urinary tract infection market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current complicated urinary tract infection treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key Takeaways from the Complicated Urinary Tract Infection Market Report
- In the year 2021, the total Complicated Urinary Tract Infection diagnosed incident cases were 8.08 Million in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
- The highest number of total Complicated Urinary Tract Infection incident cases was observed in Germany among the EU5 countries with 0.87 M cases in 2021 which are expected to grow during the study period, i.e., 2019–2032.
- The leading Complicated Urinary Tract Infection Companies are working in the market include Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, and others
- Emerging Complicated Urinary Tract Infection Pipeline Therapies in the various stages of development include Ceftazidime –avibactam, Cefepime-zidebactam (FEP-ZID), Meropenem, Doripenem, Eravacycline, Levofloxacin, CXA-101, Ceftazidime, Benapenem, Ertapenem, TBPM-PI-HBr, Ertapenem, Imipenem+Cilastatin/Relebactam, and others
- On June, 2023, Meiji Seika Pharma Co., Ltd announced a drug name is imipenem/cilastatin with phase 3. Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).
- On May, 2023, Wockhardt announced a drug name is Cefepime-zidebactam (FEP-ZID) with phase 3. This is a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with cUTI or AP.
Discover more about therapies set to grab major Complicated Urinary Tract Infection Market Share @ Complicated Urinary Tract Infection Market Outlook
Complicated Urinary Tract Infection Overview
Urinary tract infections (UTIs) are amongst the most frequent bacterial infections. They can manifest clinically in various ways, from relatively benign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis, and severe urosepsis. cUTI is a heterogeneous entity comprising multiple forms.
Complicated Urinary Tract Infection Epidemiology Segmentation in the 2032
- Total Complicated Urinary Tract Infection Occurrence-specific Cases
- Total Complicated Urinary Tract Infection Pathogen-specific Cases
- Total Complicated Urinary Tract Infection Diagnosed Cases
- Total Complicated Urinary Tract Infection Age-specific Cases
- Total Complicated Urinary Tract Infection Treated Cases
Download the report to understand which factors are driving Complicated Urinary Tract Infection Epidemiology Trends @ Complicated Urinary Tract Infection Epidemiological Insights
Complicated Urinary Tract Infection Emerging Drugs
- Tebipenem Pivoxil Hydrobromide: Spero Therapeutics
Spero Therapeutics is developing tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) as an oral antibiotic for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) to help patients avoid hospitalizations (stay at home) and/or transition patients home after IV therapy (get home).
- Sulopenem: Iterum Therapeutics
Sulopenem is an orally bioavailable, broad-spectrum penem β-lactam antibiotic which is being developed for the treatment of infections caused by multi-drug resistant bacteria. Sulopenem was discovered in the laboratories of Pfizer Inc. in the 1980s and was first developed with an intravenous (IV) formulation only. The company completed an extensive pre-clinical program, followed by human studies. Later, an oral formulation was developed and tested in Phase I and Phase II trials.
Complicated Urinary Tract Infection Treatment Market
The main course of treatment for individuals with lower UTIs is an oral medication with an empirically selected antibiotic that is effective against Gram-negative aerobic coliform bacteria, such as Escherichia coli. Currently, there are several types of medications used for treatment purposes, namely beta-lactamase inhibitors, protein synthesis inhibitors, and others. First-line antibiotics should be used to begin empiric therapy in this circumstance. Before initiating therapy, a urine sample should be sent for microscopy and culture. Severe Complicated Urinary Tract Infection can present as severe undifferentiated sepsis or even septic shock. Pharmacotherapy aims to eradicate the infection, prevent complications, and provide symptomatic relief to patients. Early treatment is recommended to reduce the risk of progression to pyelonephritis.
To know more about Complicated Urinary Tract Infection Treatment options, visit @ Complicated Urinary Tract Infection Drugs
Complicated Urinary Tract Infection Market Dynamics
The complicated urinary tract infection market dynamics is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world and rising cases of uncomplicated urinary tract infection. Key players, such as, Allecra Therapeutics, Venatorx Pharmaceuticals, Wockhardt, Spero Therapeutics etc are involved in developing drugs for Complicated Urinary Tract Infection.
Complicated Urinary Tract Infection Market Insights
Urinary Tract Infection affects any part of the urinary system, including kidneys, bladder, ureters, and urethra, has been categorized into uncomplicated and complicated urinary tract infection. Frequent sexual intercourse is one of the biggest urinary tract infection risk factors for younger women. Short-term goals are to ameliorate symptoms and prevent complications, including sepsis and death or other potential manifestations such as impaired diabetic control.
Learn more about the Complicated Urinary Tract Infection Pipeline Therapies in clinical trials @ Complicated Urinary Tract Infection Market Landscape
Scope of the Complicated Urinary Tract Infection Market Report
- Coverage- 7MM
- Study Period- 2019-2032
- Complicated Urinary Tract Infection Companies- Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, and others
- Complicated Urinary Tract Infection Pipeline Therapies-Ceftazidime –avibactam, Cefepime-zidebactam (FEP-ZID), Meropenem, Doripenem, Eravacycline, Levofloxacin, CXA-101, Ceftazidime, Benapenem, Ertapenem, TBPM-PI-HBr, Ertapenem, Imipenem+Cilastatin/Relebactam, and others
- Complicated Urinary Tract Infection Market Dynamics: Complicated Urinary Tract Infection Market Drivers and Barriers
- Complicated Urinary Tract Infection Market Access and Reimbursement
Discover more about Complicated Urinary Tract Infection Drugs in development @ Complicated Urinary Tract Infection Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Complicated Urinary Tract Infection Report Introduction
- Table of Contents
- Complicated Urinary Tract Infection Market Overview at a Glance
- Executive Summary of Complicated Urinary Tract Infection
- Key Events
- Complicated Urinary Tract Infection Epidemiology and Market Methodology
- Disease Background and Overview
- Complicated Urinary Tract Infection Treatment and Management
- Epidemiology and Patient Population
- Patient Journey
- Complicated Urinary Tract Infection Marketed Drugs
- Key Endpoints in Complicated Urinary Tract Infection Clinical Trials
- Complicated Urinary Tract Infection Emerging Drugs
- Conjoint Analysis
- Complicated Urinary Tract Infection: Seven Major Market Analysis
- Complicated Urinary Tract Infection Market Access and Reimbursement
- KOL Views
- Complicated Urinary Tract Infection SWOT Analysis
- Complicated Urinary Tract Infection Unmet Needs
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Get in touch with our Business executive @ Complicated Urinary Tract Infection Market Drivers and Barriers
Top Selling Market Research Reports in 2023
France Healthcare Outlook Report | Acute Pulmonary Embolism Market | Choroidal Neovascularization Market | Chronic Cutaneous Ulcer Market | Pulse Oximeters Market | Ankylosing Spondylitis Market | Neuroblastoma Market | Eczema Market | Chemotherapy Induced Thrombocytopenia Market | Ncfb Market | Pruritus Market | Achondroplasia Market | Blood Gas And Electrolyte Analyzers Market | Hyperinsulinemic Hypoglycemia Market | Alpha Antitrypsin Market | Concussions Market Size | Stable Angina Market | Allergic Conjunctivitis Market | Encephalitis Market | Intrahepatic Cholangiocarcinoma Market | Acute Coronary Syndrome Market | Advanced Renal Cell Carcinoma Market | Angioedema Market | Anemia Market | Foot And Ankle Devices Market | Giant Papillary Conjunctivitis Market | Hepatorenal Syndrome Market | Optic Neuritis Market
Read More about Consulting Services:
Biotech Consulting | Business Consulting Services | Consulting Services | Healthcare Business Development | Healthcare Consulting Services | Healthcare Strategy Consulting | Life Science Consulting | Life Science Consulting Firms
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj